The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension.
OBJECTIVES To compare the antihypertensive efficacy and tolerability of the imidazoline I1 receptor agonist moxonidine , a central ly acting antihypertensive , with the angiotensin converting enzyme inhibitor enalapril . DESIGN An 8-week , double-blind , r and omized , placebo-controlled study involving 140 out patients with mild-to-moderate essential hypertension . METHODS Out patients with WHO stage I or II hypertension were enrolled in the study . After a 4-week placebo-controlled stabilization phase patients were allocated r and omly to placebo , 0.2 mg moxonidine once a day or 5 mg enalapril once a day for 2 weeks . Dosages were then doubled to 0.4 mg moxonidine once a day or 10 mg enalapril once a day for a further 6 weeks . Blood pressure responses to therapy were measured by conventional office techniques and by 24 h ambulatory blood pressure monitoring . RESULTS The mean reduction in sitting blood pressure with moxonidine was similar to that with enalapril ( 19.5 + /- 16.0/12.3 + /- 8.7 versus 18.9 + /- 13.7/11.8 + /- 8.0 mmHg ) and significantly superior to that with placebo ( -4.6 + /- 12.3/-4.7 + /- 6.8 mmHg , P < 0.001 ) . In addition to reducing blood pressure during conventional measurements , moxonidine administration reduced blood pressure throughout 24 h ambulatory measurements . The trough : peak ratio for moxonidine was 0.7 . Both moxonidine and enalapril were tolerated well . CONCLUSIONS Moxonidine is an effective and well-tolerated antihypertensive , at least as good as other established forms of antihypertensive medication . The trough : peak ratio of 0.7 indicates that the drug will be effective administered once a day
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .